Cetirizine
| Evidence Level: L5 | Predicted Indications: 3 |
Table of Contents
Cetirizine: Histamine H1-receptor antagonist → nasal cavity disease
One-Sentence Summary
Cetirizine is an H1-receptor antagonist (antihistamine) that is marketed in Canada. The TxGNN model predicts it may be effective for nasal cavity disease, but no clinical trials are registered and the 5 publications found are reviews, preclinical work or studies of other drugs. The prediction therefore remains at the model-prediction stage.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | nasal cavity disease |
| TxGNN Prediction Score | 0.9977 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs on record: at least 18; dormant: 2) |
| Number of DINs | at least 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data are not available in the data compiled for this report. Based on general pharmacology, cetirizine blocks histamine H1 receptors, which are present on nerve endings, smooth muscle and glandular cells in the nose. A review of H1-antagonist action (Baroody and Naclerio) notes that this blockade is the main mechanism of antihistamines in allergic disease, and that additional anti-allergic effects may also contribute.
“Nasal cavity disease” is a very broad term. It largely overlaps with allergic and vasomotor rhinitis, where histamine-driven symptoms are plausible targets. The supporting evidence is indirect and non-specific, so this prediction offers no clearly distinct repurposing signal beyond uses already covered by existing products.
Two other model predictions, rosacea conjunctivitis (0.9941) and recalcitrant atopic dermatitis (0.9919), have no trials or literature. Their mechanistic rationale is weak, since neither condition is mainly histamine-driven, and they are not the main focus of this report.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
None of the publications below studies cetirizine in nasal cavity disease as a whole, so they do not provide direct evidence.
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 11291777 | 2000 | Review | Allergy | Describes H1-antagonist action as competitive blockade of histamine receptors, with possible additional anti-allergic effects |
| 37970776 | 2023 | Review | Vestnik otorinolaringologii | Treatment of nose and paranasal sinus inflammation should follow the pathogenesis of the inflammatory reaction |
| 35818943 | 2022 | Review | Vestnik otorinolaringologii | Modern H1 antihistamines in allergic rhinitis with comorbid acute respiratory infections |
| 36116201 | 2022 | Preclinical (mouse) | Phytomedicine | Shufeng Jiedu capsule, an unrelated intervention, in a mouse model of allergic rhinitis |
| 9301130 | 1997 | Preclinical (animal) | Arerugi | Betotastine, a different drug, in experimental allergic rhinitis; cetirizine was used as a comparator and inhibited the response dose-dependently |
Canada Market Information
Cetirizine has valid single-ingredient licences in Canada; the list below may be partial. Dosage form and indication text are not recorded in the local data.
| DIN | Product Name |
|---|---|
| 02427141 | MAR-CETIRIZINE |
| 02240266 | ALLERGY RELIEF |
| 02496488 | NAT-CETIRIZINE |
| 02315955 | EXTRA STRENGTH ALLERGY RELIEF |
| 02517566 | CETIRIZINE EXTRA STRENGTH |
Safety Considerations
- Drug Interactions: Moderate-level interactions are listed with bupropion, dronabinol, loperamide, metoclopramide, morphine (including liposomal), nabilone, opium, sibutramine, difenoxin and diphenoxylate. Several of these involve additive sedation or central nervous system effects. Further interactions of unknown severity are also listed (for example calcitriol, vitamin A, phentermine and pantoprazole).
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: No clinical trial or publication directly studies cetirizine in nasal cavity disease as a whole. The term overlaps heavily with uses already covered by existing products, so the evidence level is L5 and there is no distinct repurposing signal.
To proceed, the following is needed:
- Mechanism-of-action data
- Package insert warnings and contraindications from Health Canada
- A more specific target condition than “nasal cavity disease”, with a directly relevant clinical study
- A defined formulation and route of administration for the new use
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.